2 months UBS Group Trims Moderna (NASDAQ:MRNA) Target Price to $108.00 MarketBeat
UBS Group cut their target price on shares of Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday.
Moderna (MRNA) · Nasdaq 100 · Science
X